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ABSTRACT
Objective: New technique was adopted and validated to estimate pivotal sample size from the pilot study data and to establish bioequivalence (BE) of 
highly variable drugs (HVD), paroxetine, a novel controlled release (CR) matrix tablets utilized ghatti Gum as a rate controlling membrane, in human 
subject under fed conditions by reference scale design.
Methods: Bootstrapping technique was adopted to calculate the pivotal sample size from pilot study data for HVD paroxetine. The reliability and 
validation of the method were tested in a semi replicate three sequence (RRT, RTR, and TRR where T stand for test drug and R stand for reference 
drug) cross-over BE study in 24 healthy subjects under fed conditions.
Results: The ratio of the pharmacokinetic (PK) metric obtained from the bootstrapping technique after log transformation was 1.04 for Cmax, 1.23 for 
AUCT, and 1.21 for AUCI with corresponding power of the study which was greater than 80% from pilot study data simulation. The ratio of the PK 
metric obtained from the reference scaling design in the present study was 1.00 for Cmax, 1.21 for AUCT, and 1.17 for AUCI. The upper limit of the Cmax, 
AUCT, and AUCI at 95% confidence limit was −0.143, −0.136, and −0.17, respectively.
Conclusion: The test paroxetine CR formulation was bioequivalent with reference drug under fed conditions. The technique used for estimation of the 
sample size in the pivotal study was found reliable, and bootstrapping technique plays an important role in calculating sample size where intrasubject 
variability was immaterial.
Keywords: Reference scaling, Bootstrapping techniques, Sample size, Bioequivalence, Controlled release.
INTRODUCTION
Paroxetine hydrogen chloride (paroxetine [HCl]) is an antidepressant 
and belongs to the class of selective serotonin reuptake inhibitors 
(SSRIs) [1,2]. Paroxetine has the highest known affinity for the serotonin 
transporter (0.13 nanomoles) of any currently used antidepressant [3]. 
Paroxetine was previously reviewed as an antidepressant drug in 1991 
and reported some amount of hepatic toxicity following the chronic 
use of the drug [4,5]. Paroxetine (HCl) is now used to treat obsessive-
compulsive disorders and panic disorders [6,7]. Paroxetine (HCl) is a 
phenylpiperidine derivative and (-) enantiomer is optically active, used 
clinically [8,9]. Paroxetine (HCl) is not available in any combination 
preparations. The reason was to reduce acute toxicity and improved 
tolerability of SSRI compared to previously frequently used tri- and 
tetracyclic antidepressants [10,11]. Furthermore, controlled release 
(CR) formulation of paroxetine is highly safe and tolerable compared to 
immediate release formulation [12].
Controlled clinical trial on pharmacokinetics (PK) of paroxetine 
exhibited high variability within the subjects (>30% reference 
variability within subjects). The substantial change in the innovator 
formulation necessitates bioequivalence (BE) study as per scale-up and 
post-approval changes (SUPAC) guideline (FDA, Guideline for industry, 
1997) for registration of the generic product [13]. FDA proposed scaled 
average BE (SABE) study in 2008 to establish BE of highly variable 
drugs (HVD) with a minimum subject of 24 [14,15]. The most important 
feature of the SABE study is that a fixed sample size is adequate to 
demonstrate BE regardless of within-subject variability. In the present 
study, bootstrap technique is used to fix sample size and to calculate 
test/reference (T/R) ratio and power of the study from pilot data. Hence, 
the aim of the current research was to estimate sample size calculation 
and validation by bootstrapping techniques from the pilot study. The 
other aim of the study was to establish BE of paroxetine 37.5 mg CR 
tablets by adopting three-period, three-sequence, two-treatment 
reference replicate (SABE) proposed by regulatory agency [16].
MATERIALS AND METHODS
Materials
Paroxetine and fluoxetine were obtained from Lupin Bioresearch 
Center, Mumbai, India. Acetonitrile, n-hexane, and methanol were 
procured from Sigma-Aldrich, Bengaluru, India. Analytical grade formic 
acid, amyl alcohol, and sodium hydroxide were purchased from local 
chemical store. Water was purified using in-house Milli-Q-System. 
All chemicals used for method development and validation were of 
analytical grade.
The liquid chromatography (LC) system used was API4000 AB SCIEX 
(California, USA) LC system equipped with triple-quadrupole mass 
analyzers and XBridge OST (BEH) C 18 column (50 mm×4.6 mm, 2.5 µ 
particle size with a pore size of 130 A0). A Phenomenex SecurityGuard 
column (Bester, 4.0×2.0 mm) was used to protect the original column.
Methods
Formulation development
Extended-release (ER) matrix tablets were prepared by wet granulation 
technique [17]. The exact quantity of drug and inactive ingredients 
(Table 1) was passed through sieve #40 and mixed thoroughly in 
octagon blender. The blend was mixed with isopropyl alcohol to make 
a dough mass which was then transferred to rapid mixture granulator 
to get wet granules. The wet granules were dried at room temperature 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i5.32319
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70°C for about 15 min. The dried granules were then passed through 
sieve no 20. The extra-granular lubricant talc was mixed with granules 
and finally punched by a 27 station rotary tablet punching machine. 
The list of inactive ingredients used for the formulation of the tablets 
is given in Table 1.
High-performance LC method development for the quantification 
of paroxetine in human plasma
Various methods have already been established to quantify paroxetine in 
biological fluids [18-29]. Such methods include gas chromatography (GC) 
with nitrogen and mass spectrometry (MS) detection or simultaneous 
estimation with the same chemical category compounds by LC-tandem 
mass spectrometry (LC-MS/MS) or GC-MS or LC with voltammetric 
detection or LC with ultraviolet or MS analysis. However, in the present 
study, low solvent consuming and best recovery MS analysis method 
was applied to quantify picogram level of drug concentration in human 
plasma. The method was validated with respect to liquid-liquid extraction, 
reversed-phase LC, and MS/MS detection to perform the selective 
determination of paroxetine. Tandem MS was selected to improve 
the selectivity and sensitivity of the method of determination. The LC 
conditions, composition of mobile phase, and the MS/MS optimization 
were investigated to select the most appropriate operating conditions. 
The validation of the method was performed with respect to parameters 
such as linearity of the chromatographic response, precision, and accuracy 
which meets the accepted criteria for bioanalytical method validation and 
employed in BE study of two paroxetine 37.5 mg ER tablets.
Preparation of calibration curve
A stock solution of paroxetine was prepared in methanol to obtain a 
concentration of 1000 µg/L. An aliquot of the solution was evaporated to 
dryness and reconstituted with blank plasma and vortexed for 15 min to 
get a final concentration of 1 µg/L. From this solution, eight calibration 
standard solutions containing 200, 500, 1000, 2000, 4000, 6000, 8000, 
and 10,000 ng/L and three quality control solutions at concentrations 
of 500, 5000, and 10,000 ng/L were prepared in blank plasma. The 
stock solution of fluoxetine was prepared in methanol and aliquot of 
the solution was evaporating to dryness and used as internal standard 
(IS). The dried IS was reconstituted with blank plasma and vortexed for 
15 min to get a final concentration of 1 µg/L. The calibration curve of 
paroxetine in blank human plasma and fluoxetine as IS is given in Fig. 1.
Preparation of plasma sample for analysis
Extraction of paroxetine from human plasma sample was carried 
out following addition of 100 mg NaCl, 200 µl of 0.1 M NaOH, 5 ml 
hexane:isoamyl alcohol (99:1, v/v), and 20 µL (1 µg/L) of IS to 0.5 ml 
plasma sample. The mixture was vortexed for 15 min and centrifuged 
at 3000 rpm for 15 min at 4°C to separate an organic phase. 5 mL of 
the supernatant solution was transferred to 10 ml Eppendorf vial and 
evaporated to dryness after addition of 50 µL of 1N HCL. The dried mixture 
was reconstituted with mobile phase (solution of formic acid [0.1%] in 
acetonitrile:water [6:4 v/v] pumped at a flow rate of 0.15 mL/min).
Validation of the method
The recovery of paroxetine was determined in three different QC 
samples having concentrations of 500, 5000, and 10,000 ng/L in blank 
blood plasma. Plasma samples with the added drug at the concentrations 
specified above were extracted in triplicate. The concentrations of these 
samples were calculated on the basis of calibration curves constructed 
from the data for the drug not subjected to the extraction procedure.
To determine the intraassay precision, aliquots (n=6) of blank plasma 
containing the standard solution of paroxetine at concentrations of 
500, 5000, and 10,000 ng/L were analyzed by the method proposed. To 
determine the interassay precision, blank plasma containing standard 
solution at the specified concentration was analyzed on 5 consecutive 
days. Linearity was obtained by analyzing control plasma samples (n=6) 
containing standard solutions of paroxetine at concentrations of 500–
10,000 ng/L. The concentration range was estimated on the basis of the 
regression curve (Y=1.004X+0.0045, R2=0.999) (Fig. 1) and correlation 
coefficient. The limit of quantification was determined by analyzing 
blank plasma samples enriched with decreasing concentrations 
of paroxetine standard solution. The limit of quantification was 
considered to be the lowest concentration quantified with an error of 
<10% for a sample size of 5. The selectivity of the method was evaluated 
by analyzing several drugs combined with paroxetine. The drugs that 
presented retention times close to those of the drugs under the study 
were submitted to the extraction procedure and rechromatographed.
Table 1: List of inactive ingredients used for the formulation of 
tablets
Test drug Reference drug
Hypromellose Hypromellose
Lactose monohydrate Lactose monohydrate
Ghatti gum Polyethylene glycol
Purified talc Purified talc
FD and C yellow No. 6 
aluminum lake
FD and C yellow No. 6 aluminum lake
D and C yellow No. 10 
aluminum lake
D and C yellow No. 10 aluminum lake
Ghatti gum Polymethyl methacrylate
Polysorbate 80 Polysorbate 80
Sodium lauryl sulfate Sodium lauryl sulfate
Titanium dioxide Titanium dioxide
Fig. 1: Calibration curve of the paroxetine in blank human plasma using fluoxetine as internal standard in MRM mode 
(Y=1.004X+0.0045, R2=0.999)
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BE study
Twenty-six healthy male Indian volunteers aged between 18 and 
45 years with body mass index (BMI) within 19–29.4 kg/m2 were 
enrolled for the study after assessment of their health status by general 
physical examination and clinical laboratory evaluation (including 
electrocardiogram [ECG] and chest X-ray). The normal value range 
of the following laboratory tests: Albumin, alkaline phosphatase, 
aspartate aminotransferase (AST), aminotransferase (ALT), blood 
glucose, creatinine, μ-GT, total bilirubin, total protein, triglyceride, total 
cholesterol, hemoglobin, hematocrit, total and differential white cell 
counts, routine urinalysis, and negative serology for HIV, HBV, and HCV 
were determined before enrolling them in the study. All the subjects gave 
written informed consent, and the Madras Ethics Committee, Chennai, 
Tamil Nadu, India, approved the clinical study protocol. The study was 
conducted in accordance with ICH GCP, Indian GCP, ICMR guideline with 
the provisions of the Declaration of Helsinki (Seoul 2008).
The study was an open-labeled, randomized, three-sequence, three-
period, single-dose, reference replicated three-way crossover design 
with 14 days’ washout period between the doses. During each period, 
the volunteers were housed in a clinical pharmacology unit of Huclin 
Research Limited, Chennai, Tamil Nadu, India, on the eve of the dosing 
day. Following overnight fasting of about 10 h a high calorie, high fat 
breakfast was served 30 min before the study drug administration. 
A single dose of paroxetine (37.5 mg CR tablets of test or reference 
either formulation) was administered orally to each of the volunteers as 
per randomization code list at sitting posture with the aid of 240 ml of 
water in a staggered manner to easy sample collection. A mouth check 
following drug administration, with the help of a tongue depressor, 
was performed for each of the volunteers to ensure the compliance of 
the dosing activities. All the subjects were restricted to 2 h post-drug 
administration water intake and toileting, while at other time, water 
was given ad libitum. A standard meal was provided to all the volunteers 
at 4, 8, and 12 h post-drug administration. Vitals were recorded at 2, 4, 
6, 8, 12, and 24 h post-drug administration for each volunteer to assess 
any health-related complication. No other food was permitted during 
the “in-house.” Serial blood samples were collected from each of the 
volunteers at every period at pre-dose and at 04.00, 06.00, 08.00, 10.00, 
12.00, 14.00, 16.00, 18.00, 20.00, 24.00, 28.00, 36.00, 48.00 72.00, and 
96.00 h post-drug administration.
Sample size estimation for pivotal study
A pilot study was conducted among 12 subjects in three-period, three-
sequence, cross-over design under fed conditions to establish sample size 
in the pivotal study. The within-subject reference variability of the area 
under the paroxetine plasma concentration-time curve from time 0 to the 
last measurable concentration (AUCT) and maximum drug concentration 
(Cmax) was >0.3 and the T/R ratio of the drug was 1.27 and 1.3, respectively. 
Based on the result of the pilot study, 6 test and 12 reference subject data 
were randomly selected from the pool of 36 individual subject data for all 
the three periods. The resultant 18 (1:2) subjects were considered as a 
boot sample and reanalysis the data to find the T/R ratio then simulate 
to 36, 45, 54, 60, 72, 90 and 108 boot samples and then recalculate the 
T/R ratio; this procedure was continued until T/R ratio was within 0.80–
1.25. The simulation which produces the T/R ratio within the limit of 0.8 
to 1.25 was considered the final sample size for the pivotal study ignoring 
the subjects and sequence effect in the bootstrap analysis. To confirm the 
sample size, a power calculation was done further by resampling up to 
1000 times from the boot sample and individual calculation of PK metric 
to find the ratio (Fig. 2).
Finally, the power was calculated based on the percentage of the time, and 
the ratio was within 80–125 from thousand bootstrapping [30-34]. If the 
power was failed to meet 80%, then nearest boot sample was considered 
for further analysis to adjust the power of the study. In the present study, 
72 boot samples were matched with the criteria of ratio between 80% 
and 125% which corresponds to a total number of subjects in the three-
period design as 24 (72/3). Hence, 24 subjects were included in the 
study; the bootstrapping simulation of the data of 72 samples produced 
the T/R ratio of 1.23 for Cmax and 1.21 for AUCT after simulation.
PK analysis
Data from all subjects who completed all the three periods of the study 
were analyzed, and 24 subject data were used for PK and statistical 
analysis. The PK parameters of paroxetine were estimated using non-
compartmental techniques [35]. The Cmax and the time elapsed to 
Cmax (Tmax) were obtained directly from the data. The terminal-phase 
elimination rate constant was obtained using log-linear regression of 
the last four non-zero concentrations. The area under the paroxetine 
plasma concentration-time curve from time 0 to the last measurable 
concentration (AUCT) was computed using the linear trapezoidal 
rule. The area under the plasma concentration-time curve from time 
0 to infinity (AUCI) was calculated as the sum of AUCT and Ct/Kel, 
where Ct was the last measurable concentration. The elimination half-
life was calculated as ln(2)/Kel. All the PK analyses were performed 
by WinNonlin Professional, version 5.0.1 (Pharsight Corporation, 
Mountain View, California).
Within subject reference variability
From three-period designs, sequence term was used to extract 
reference treatment effect and residual mean square for calculating 
reference variability assuming reference crossed with reference as 
like of conventional two-way cross-over study [36,37]. BE testing of 
paroxetine was performed using a partial replicate three-way cross-
over design, and within-subject variability of primary PK parameters 
was calculated using mean square error (MSE) of log-transformed 
primary PK parameters (Equation 1).
       Within subject reference variability =( EXP (MSE)-1 )×100  (1)
The MSE was calculated by generalized linear modeling (GLM) procedure 
in SAS V 9.1.3 using sequence term to separate the cross-reference [38]. 
Fig. 2: Sample size and power estimation by 1000 boot samples analysis
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The within-subject variability of paroxetine was used as critical criteria 
for its identification as a HVD and was an important parameter for the 
application of SABE and population bioequivalence [39].
Statistical analysis of PK data
The data were analyzed for normal average BE as well as reference scale 
average BE, and the statistical differences between the two approaches 
were evaluated. All the statistical analyses were performed by SAS V 9.2 
(SAS Inc., Carry, USA). The primary PK parameters, namely AUCT, AUCI, 
and Cmax, were log transformed to get parametric distribution, and log-
transformed data were subjected to ANOVA analysis. A GLM procedure 
was used to evaluate formulation period and sequence effects on the 
primary PK parameters. The model included all primary PK parameters 
as main effect subjects nested within the sequence as random effect and 
sequence, period, and formulation as fixed effect [40]. The significance 
of all fixed effects was tested at alpha 0.05 and random effects at alpha 
0.1 [41,42].
Reference variability between subjects and within-subjects was 
calculated by the use of SAS program for reference scaled approach as 
prescribed by the FDA for establishing the bioavailability of HVD.
The ratio of all primary PK parameter such as AUCT, AUCI, and Cmax was 
also analyzed by the same program using PROC GLM model. The 90% 
confidence intervals (CIs) of the test/reference ratios for AUCI and 
Cmax were determined. Following national and international guidelines 
(including those of the FDA), the test and reference formulations were 
considered bioequivalent if the 90% CIs for the test/reference ratios of 
the log-transformed AUCI and Cmax mean values were between 0.80 and 
1.25, and as per reference scaled approached point estimate of the ratio 
of PK parameters should fall within the 0.80–1.25 limit to show the BE 
as per FDA guidelines for HDV in a scale average BE approach and 95% 
CI upper limit of the test to reference PK metric will be less than zero.
In addition, a non-parametric analysis (Wilcoxon signed-rank test) 
was applied to compare Tmax for both formulations. Non-parametric 
population characteristics were described with median and range.
Statistical evaluation of average BE
Average BE (ABE) was applied for BE assessment of paroxetine in 24 
healthy human male subjects. ABE was assessed using a two one-sided 
hypothesis testing procedure as follows [43].
  H0: log(1.25)≤(µT−µR)≤log(0.80) (2)
Versus
  H1: log(0.8)<(µT−µR)<log(1.25) (3)
Where µT and µR are the mean for test and reference formulations 
adjusted for period and sequence effects on a log-transformed scale, 
respectively. ABE was concluded as the 90% CI for the ratio of test to 
reference limits within 0.80−1.25 for all PK parameters.
Statistical evaluation of SABE
SABE is also considered as scaled individual BE. There is no subject by 
formulation interaction and the same within-subject variability of two 
drug products. Difficulties arise to establish BE for that drug product 
which fall under the categories of within-subject reference variability 
≥30%.
However, the scientists from FDA working group on HVD proposed the 
approach of reference SABER for the determination of BE in the case 
of HVD [44]. This method suggests that, if the expected intrasubject 
variability of a drug is <30%, the classic 0.80–1.25 limits should be 
applied. However, for drugs with CVWR exceeding 30%, a reference 
SABE approach should be used. These suggestions correspond to a 
switching coefficient of variation of CVw0=30%. It was proposed that 
three-period BE studies should be performed in which the reference 
product will be administered twice and the test product once, i.e., the 
possible sequences are TRR, RTR, and RRT. SABE was used to establish 
the BE of paroxetine using a minimal number (n=24) subjects. The 
formula used to expand the BE limit is given below of the SABER 
criterion as described by equation 4.
 
  swrUpper / Lower BE limits = Exp [±ln 1.25 * ]swo  (4)
Where swr=Within-subject reference standard deviation (SD) and 
swo=Switching variability or regulatory limits.
SABE is concluded if the upper limit to the ratio of test to reference is 
zero or less than zero at 95% CI and the GMR of this parameter is within 
0.8–1.25 to reduce the probability of type 1 error.
RESULTS
The generic paroxetine tablets were prepared using hypromellose, 
polyvinylpyrrolidone, ghatti gum, and glyceryl behenate. Polyethylene 
glycol and polymethyl methacrylate of the innovator formulation 
were replaced by ghatti gum. The list of other ingredients used in the 
development of the generic formula is given in Table 1. As per SUPAC 
guideline, changing one of the inactive ingredients from the innovator 
formula is considered to be major change. To obtain regulatory approval 
(USFDA) of the generic formulation with different inactive ingredients 
in comparison with reference listed drug require in vivo BE evaluation 
in human subjects. Hence, an in vivo BE study was conducted as per the 
FDA and EU guidelines to establish BE of developed generic formulation 
for marketing approval in the present study.
Twenty-six healthy adult male subjects were enrolled, 24 of whom 
completed all the periods of the study. The baseline demographic 
characteristics of the participants were expressed in terms of mean±SD 
(range): Age, 36.65±7.94 years (22–45); height, 169±12 cm (156–181); 
and body weight, 58.34±4.37 kg (45–72). One subject withdrew due to 
abnormal results on liver function tests (described later) before period 
3. This subject’s liver function test results returned to normal within 
1 month. One subject discontinued the study prematurely for reasons 
other than investigational drug-related adverse events or serious 
adverse events.
The mean PK parameters observed after the administration of the 
various regimens are summarized in Table 2 for reference drug and 
Table 3 for test drug.
The mean plasma concentrations after the administration of paroxetine 
CR tablet with water are shown in Figs. 3 and 4.
A short lag time in maximum absorption after the administration of 
paroxetine CR tablets was observed for test drug. However, there was 
no difference in PK parameters observed for both the formulation.
Treatment-emergent adverse events were reported by 45.8% of the 
subjects (11/24) dosed during the study. Most of the adverse events 
were mild. Headache was the most common adverse event and was 
reported by 9.1% of subjects (2/22) with regimen A, 20.0% of subjects 
(4/20) with regimen B, 21.7% of subjects (5/23) with regimen C, and 
20.0% of subjects (4/20) with regimen D. Before dosing in period 4, 
one subject was found to have abnormal liver function test results (AST, 
270 U/L; alanine ALT, 875 U/L; lactate dehydrogenase, 658 U/L; and 
alkaline phosphatase, 252 U/L). At the final follow-up assessment, all 
levels had returned to within their respective normal ranges.
The linear mean plasma concentration versus time curves of test 
and reference paroxetine formulations to the 24 subjects under 
fed condition are given in Figs. 3 and 4, respectively. The primary 
and secondary PK parameters for both the formulations under fed 
condition are tabulated in Tables 2 and 3. The descriptive statistics 
for untransformed PK parameters for both the formulations under fed 
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condition is presented in Tables 2 and 3, respectively. The mean (±SD) 
Cmax (ng/L) of test and reference formulations is 8195.9 (±5091.5) and 
9701.3 (±8266.3), respectively. The mean (±SD) AUCT (ng/L*h) of test 
and reference is 272185 (±145972) and 297102 (±267131), while 
mean (±SD) AUCI (ng/L*h) of test and two reference formulations is 
290550 (±166822) and 339057 (± 338283), respectively. The mean 
(±SD) of Tmax (h), Kel (h−1), and thalf (h) of test and reference formulations 
of paroxetine is 17.7 h (±5.7) and 17.1 h (±6.7), 0.05 h−1 (±0.21) and 
0.05 h−1 (±0.17), and 11.0 h (±27.8) and 18.4 h (±10.6), respectively. The 
results of descriptive statistics of primary PK parameters of test and 
two reference products are presented in Tables 2 and 3, respectively. 
The reference variability (within-subject reference variability) of the 
primary PK parameters of Cmax, AUCT (AUClast), and AUCI (AUC total) 
is 0.58, 0.72, and 0.74, respectively. Details are presented in Table 4. 
The geometric mean ratio between two formulation and 95% CI for 
the primary PK parameters calculated from the ANOVA was 100%, 
−0.143113; 121%, −0.136539; and 117%, −0.170342, respectively 
(Table 4) meeting the criteria of scale average BE.
All the 24 subjects completed all the three periods of the study and 
there was no drop out or withdrawal. No serious adverse events 
were reported except abdominal pain in subject 01 and mild 
diarrhea in subject 02. However, such complications were resolved 
without sequel. There were no clinically significant changes in vital 
signs, clinical laboratory variables, ECG, X-ray, and general physical 
examination.
Table 3: Individual subject pharmacokinetics parameters after test treatment (fed conditions) (n=24)
Statics Kel (h−1) Thalf (h) Tmax (h) Cmax (ng/L) AUCT (ng/L*h) AUCI (ng/L*h)
Mean 0.050 16.576 17.667 8195.932 272185.417 290550.049
SD 0.021 7.785 5.710 5091.449 145972.357 166821.804
Minimum 0.02 7.09 10.00 1046.68 23826.81 25542.89
Median 0.05 14.45 17.00 7171.07 258468.09 273805.94
Maximum 0.10 35.32 28.00 20242.99 534277.73 644989.53
CV% 41.7 47.0 32.3 62.1 53.6 57.4
Geometric mean 0.046 15.178 16.880 6663.217 217943.875 229617.563
95% CI lower 0.004 −0.558 5.099 −3010.272 −49097.573 −76622.265
95% CI upper 0.095 33.710 30.235 19402.135 593468.407 657722.364
SD: Standard deviation, CI: Confidence interval, CV: Coefficient of variation
Fig. 3: Linear mean plasma concentration of paroxetine reference product at three different periods under fed conditions (n=48)
Fig. 4: Linear mean plasma concentration of paroxetine test product at three different periods under fed conditions (n=24)
Table 2: Descriptive statistics of pharmacokinetic parameters after reference treatment (fed conditions) (n=48)
Statistics Kel (h−1) Thalf (h) Tmax (h) Cmax (ng/L) AUCT (ng/L*h) AUCI (ng/mL*h)
Mean 0.046 18.376 17.083 9701.246 297101.712 339057.078
SD 0.017 10.595 6.672 8266.247 267131.434 338282.858
Minimum 0.01 9.71 10.00 761.96 10630.02 11676.93
Median 0.05 13.26 15.00 7383.74 215353.70 218855.63
Maximum 0.07 52.65 28.00 35161.33 984853.59 1376373.59
CV% 37.3 57.7 39.1 85.2 89.9 99.8
Geometric mean 0.042 16.359 15.943 6635.088 179606.618 196337.926
95% CI lower 0.011 −3.541 3.281 −7398.790 −255501.763 −360734.331
95% CI upper 0.082 40.293 30.885 26801.281 849705.187 1038848.486
SD: Standard deviation, CI: Confidence interval, CV: Coefficient of variation
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DISCUSSION
The generic paroxetine 37.5 mg ER tablets were prepared using 
hypromellose, polyvinylpyrrolidone, ghatti gum, and glyceryl behenate. 
Polyethylene glycol and polymethyl methacrylate in the innovator 
formulation were replaced by ghatti gum. The list of other ingredients 
used in the development of the formula is given in Table 1. The ghatti 
gum was used to serve as a rate-controlling membrane for the ER 
formulation. Due to the change of the inactive ingredients, a BE study 
was needed to get regulatory approval of the drug for marketing. 
Keeping this in the mind, BE study was conducted under fed conditions. 
The inherent nature of the molecule was to behave differently in 
in vivo while dosing at the same individual at different occasion. Such 
variability was observed for all the primary PK parameters (GSK clinical 
trial registry study identifier, PCR: 112811 and 112812). Due to high 
variability observed in the PK parameters, it was needed more number 
of subjects to establish BE between dosage forms by a traditional 
average BE in two-way cross-over design. To avoid exploiting a large 
number of healthy volunteers, a reference scale approach was adopted 
to establish BE. The reference scale utilizes the reference variability 
>30%; if a PK metric shows that it variability between reference is 
<30%, then conventional BE approach will be adopted; otherwise, 
95% CI test to reference ratio upper limit should be negative and test 
to reference ratio should be within 0.8–1.2 to claim BE. The method 
utilized two reference administration in the same subject at different 
periods and one test administration at another period; therefore, 
three-period, three-sequence, cross-over design was ideal to calculate 
reference variability.
This study was open-labeled, three-period, three-sequence, two-
treatment cross-over design utilizing minimum subjects of 26 under 
fed conditions. A randomization was generated to eliminate the bias 
of selecting test and reference drug for subjects. The descriptive 
statistics of age, height, weight, and BMI of the 24 subjects 
participated in the study was within the limit of 18–45 years, 1.48–
1.78 m, 55–75 kg, and 19–29.4 Kg/m2, respectively. The drugs were 
dosed on the dosing day to the volunteers as per randomization code 
list 30 min after the completion of the high-fat high-calorie breakfast. 
The study-related procedure and blood collections were done at the 
scheduled time to quantify the plasma concentration of the drug. 
There were no reported serious adverse events, signifying that the 
Ghatti gum used for the development of the generic formulation is 
well tolerable in the human subject. Since the ghatti gum obtained 
from the natural sources, some microbial contamination will always 
be present after finest purification too. Therefore, it is obvious that 
there will be some amount of temperature rising following intake 
of the gum, but in our study, it was found that there were no such 
complications regarding fever to the subject which indicated the 
safety of the ghatti gum.
Both paroxetine and IS were extracted from plasma samples by solid-
phase extraction using OASIS HLB extraction plates. Then, the plasma 
samples were washed further with a water:methanol (80:20, v/v) 
mixture. Mixtures containing varying percentages of methanol were 
tried. The 80:20 mixtures gave optimum results in terms of recovery 
and selectivity. The recovery of methanol:water mixture was not stable, 
and hence, the eluate was evaporated and the residue was reconstituted 
with mobile phase. A validated LC-MSMS method was used to quantify 
drug in the plasma samples. An eight-point calibration standard curve 
in human plasma, ranging from 200 to 10000 ng/L for paroxetine, was 
prepared in duplicate for each run. The standard curve was satisfactorily 
described by linear regression weighted by 1/x, as the back calculated 
values were all within 61.5% of the nominal concentrations (62.0% 
at the LLOQ) in the three validation runs, which are not shown in the 
result. 26 of 24 enrolled subjects completed all the three periods of the 
study.
The PK profile of paroxetine, a single dose three-period, three-
sequence, two-treatment cross-over reference replicate study with a 
minimum wash-out period of 14 days, carried out in fed conditions was 
considered to be adequate. The linear mean (±SD ng/L) concentration 
versus time graph of the reference formulation in three different 
periods is given in Fig. 3 and of test in Fig. 4. The descriptive statistics 
of PK parameters of test and reference drug are given in Tables 2 and 
3, respectively. A test drug is considered to be pharmacokinetically 
equivalent, i.e., bioequivalent to a reference drug product if the 95% 
CI of the test and reference geometric mean ratios of the AUCs and 
Cmax is found to be zero or less than zero and point estimates are in 
the range of 0.8–1.2. The appropriateness of the reference scaling 
approach was established from the SWR values of the primary PK 
parameters (Cmax, AUCT, and AUCI which were 0.58, 0.74, and 0.78, 
respectively); established primary PK parameters from this study at 
95% CIs were within the pre-defined BE criteria (Table 4). The study 
results revealed that the two formulations of paroxetine were similar 
in PK characteristics among these healthy Indian subjects under fed 
conditions.
CONCLUSION
The sample size calculation for SABE from the pilot data using 
bootstrapping resampling techniques was adequate to estimate T/R 
ratio with only 1% deviation from the observed data. The LC-MSMS 
method used for the analysis of plasma samples was reliable with a 
good reproducibility of the results. The reference scale semi-replicate 
three-period, three-sequence, two-treatment in vivo clinical study was 
adequate to establish the difference of their geometric mean for all the 
primary PK metric.
There were no serious adverse events of the study and no change in 
the abnormal laboratory value for the subjects except diarrhea to the 
subjects 20 and 18 in period two and subject 13 in period three which 
were mild in nature and resolved without sequel.
The assumption of reference scaling for the BE study is proved 
since the within-subject reference variability (SWR) for Cmax, AUCT, 
and AUCI is 0.58, 0.72, and 0.73, respectively, under fed conditions; 
therefore, reference scaling approaches were used to establish BE 
and test product found BE with respect to the reference formulation, 
and hence, we can conclude that the ghatti gum can be used as 
rate-controlled membrane in certain concentration to develop CR 
formulation of other drugs.
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